Beta Bionics, Inc. (BBNX) Receives a Buy from Truist Financial
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Richard Newitter assigned a Buy rating to Beta Bionics (BBNX) with a $28 price target. This follows a recent Buy from Wells Fargo, while Robert W. Baird maintains a Hold rating.
In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Beta Bionics, Inc., with a price target of $28.00.
According to TipRanks, Newitter is a 4-star analyst with an average return of 5.9% and a 47.67% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific, Dexcom, and Zimmer Biomet Holdings.
In addition to Truist Financial, Beta Bionics, Inc. also received a Buy from Wells Fargo’s Larry Biegelsen in a report issued yesterday. However, on September 15, Robert W. Baird maintained a Hold rating on Beta Bionics, Inc. (NASDAQ: BBNX).